Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation
暂无分享,去创建一个
T. Munro | A. Palkova | J. Marks | S. Mahler | M. Jones | R. Barnard | K. Braet | Y. Fan | P. Fromm | K. Bradstock | T. Seldon | R. Pryor | N. Verma | M. Findova | Y. Sheng | E. Y. Zhou | P. Silveira | Z. Elgundi | X. Ju | G. Clark | D. Munster | D. Hart
[1] Meredith O'Keeffe,et al. Dendritic cell subsets. , 2017, Seminars in cell & developmental biology.
[2] P. Harden,et al. Predictors of Cancer Risk in the Long-Term Solid-Organ Transplant Recipient , 2014, Transplantation.
[3] Yanna Ma,et al. Regulatory Dendritic Cells for Immunotherapy in Immunologic Diseases , 2013, Front. Immunol..
[4] R. Lechler,et al. Tolerogenic Donor-Derived Dendritic Cells Risk Sensitization In Vivo owing to Processing and Presentation by Recipient APCs , 2013, The Journal of Immunology.
[5] P. Parren,et al. Crosstalk between Human IgG Isotypes and Murine Effector Cells , 2012, The Journal of Immunology.
[6] A. Hoitsma,et al. Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation , 2012, Expert opinion on biological therapy.
[7] A. Thomson,et al. Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. , 2012, Blood.
[8] P. Matzinger. The evolution of the danger theory , 2012, Expert review of clinical immunology.
[9] D. Roopenian,et al. Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross-presentation and the appearance of cross-presentation. , 2011, Blood.
[10] B. Malissen,et al. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease , 2011, Nature Medicine.
[11] Martina L. Jones,et al. Improved Protein-A separation of V(H)3 Fab from Fc after papain digestion of antibodies. , 2011, Journal of biomolecular techniques : JBT.
[12] Leonard A. Smith,et al. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. , 2011, Protein engineering, design & selection : PEDS.
[13] E. Elder,et al. GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression. , 2010, Blood.
[14] J. Marks,et al. Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. , 2010, Journal of molecular biology.
[15] T. Munro,et al. A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies. , 2010, Journal of immunological methods.
[16] A. Enk,et al. Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance? , 2009, Human immunology.
[17] A. Palkova,et al. Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease , 2009, The Journal of experimental medicine.
[18] A. M. Burns,et al. Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem-Cell Transplant Determines the Kinetics of Acute Graft-Versus-Host Disease , 2008, Transplantation.
[19] T. Mak,et al. The CD83 reporter mouse elucidates the activity of the CD83 promoter in B, T, and dendritic cell populations in vivo , 2008, Proceedings of the National Academy of Sciences.
[20] M. Probst-Kepper,et al. CD83 Expression in CD4+ T Cells Modulates Inflammation and Autoimmunity1 , 2008, The Journal of Immunology.
[21] B. Fleischer,et al. CD83 regulates lymphocyte maturation, activation and homeostasis. , 2008, Trends in immunology.
[22] J. Lau,et al. Activated Circulating Dendritic Cells After Hematopoietic Stem Cell Transplantation Predict Acute Graft-Versus-Host Disease , 2007, Transplantation.
[23] P. Carter. Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.
[24] Ying Tang,et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. , 2005, Journal of molecular biology.
[25] D. Jain,et al. Donor APCs are required for maximal GVHD but not for GVL , 2004, Nature Medicine.
[26] K. MacDonald,et al. Characterization of human blood dendritic cell subsets. , 2002, Blood.
[27] B. Hock,et al. A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. , 2001, International immunology.
[28] M. Shlomchik,et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.
[29] J. Gerhart,et al. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[30] S. Gallinger,et al. A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes. , 1995, Transplantation.
[31] Liangji Zhou,et al. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. , 1995, Journal of immunology.
[32] B. Hock,et al. Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. , 1994, Immunology.
[33] G. Winter,et al. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. , 1992, Journal of molecular biology.
[34] J. McKenzie,et al. THE EFFECT OF DONOR PRETREATMENT ON INTERSTITIAL DENDRITIC CELL CONTENT AND RAT CARDIAC ALLOGRAFT SURVIVAL , 1984, Transplantation.
[35] Fabre Jw,et al. Mechanism of induction of passive enhancement. Evidence for an interaction of enhancing antibody with donor interstitial dendritic cells. , 1982 .
[36] C. Bollard,et al. Complications of transplant for nonmalignant disorders: autoimmune cytopenias, opportunistic infections, and PTLD. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[37] Xenia Luna,et al. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. , 2010, Human antibodies.
[38] S. Giralt,et al. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[39] Masato Kato,et al. Human T lymphoblasts and activated dendritic cells in the allogeneic mixed leukocyte reaction are susceptible to NK cell-mediated anti-CD83-dependent cytotoxicity. , 2004, International immunology.